OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
NEW ORLEANS, Sept. 02, 2016 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 19, 2016 to file lead plaintiff applications in a securities class action lawsuit against Emergent BioSolutions, Inc. (NYSE:EBS), if they purchased the Company’s securities between January 11, 2016 and June 21, 2016, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Maryland.
What You May Do
If you purchased shares of Emergent and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by September 19, 2016.
About the Lawsuit
Emergent and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The alleged false statements include, but are not limited to, that the U.S. government’s demand for Emergent’s anthrax vaccine (BioThrax) was strong and growing and Emergent believed the government would renew its 5-year exclusive anthrax vaccine procurement contract.
On June 22, 2016, it was revealed that the U.S. Department of Health and Human would be purchasing less BioThrax, purchase doses of a next-gen anthrax vaccine when one was approved, and seek bids from other companies for the remainder of its anthrax vaccine procurement.
On this news, the price of Emergent’s shares plummeted.
About Kahn Swick & Foti, LLC
KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 206 Covington St. Madisonville, LA 70447
